United States · 
Who invested in Molecular Biometrics?
Molecular Biometrics's investors include Safeguard Scientifics, Atlas Venture and Oxford Bioscience Partners.
20092010
$12MSeries A$13MSeries BUnited States · Series B startup
Who invested in Molecular Biometrics
2 rounds we have observed, with the 3 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$25Mraised across 2 rounds since 2008, from 2 sources
$12MSeries A$13MSeries B
- Latest round
- Series B, $13MJan 2010
- Investors
- 3
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Series A, $12M Nov 2008
- Biggest round
- $13M Series B · Jan 2010
- Between rounds
- 14 months from the last two
The rounds
- Jan 2010Series B$13M2 new1 returning
Reported by finsmes.comSEC filing: $13M sold, first sale Dec 2009
- Nov 2008
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
Oxford Bioscience PartnersGrowth equity1round
Missing a round, or an investor who was in one? Tell us.
Quick answers about Molecular Biometrics
How much has Molecular Biometrics raised?
Molecular Biometrics has raised $25M across 2 rounds since 2008.
When did Molecular Biometrics last raise?
Molecular Biometrics's most recent round was a Series B of $13M in Jan 2010.
What was Molecular Biometrics's biggest round?
Its most recent round, $13M in Jan 2010, is also its largest on record.
Who backed Molecular Biometrics first?
Molecular Biometrics's first round on record, in Nov 2008, was backed by Safeguard Scientifics.
What stage is Molecular Biometrics at?
Molecular Biometrics's latest named round is a Series B, in Jan 2010.
Where is Molecular Biometrics based?
Molecular Biometrics is based in the United States.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.